NASDAQ:PCRX Pacira BioSciences (PCRX) Stock Price, News & Analysis $14.54 +0.21 (+1.47%) (As of 09/27/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Pacira BioSciences alerts: Email Address About Pacira BioSciences Stock (NASDAQ:PCRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pacira BioSciences alerts:Sign Up Key Stats Today's Range$14.19▼$14.7550-Day Range$11.70▼$22.3652-Week Range$11.16▼$35.95Volume632,728 shsAverage Volume1.14 million shsMarket Capitalization$670.73 millionP/E Ratio10.17Dividend YieldN/APrice Target$24.10Consensus RatingHold Company OverviewPacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.Read More… Don’t wait for FDA approval (Ad)Don’t let Wall Street fool you. AI is not the only hot sector in the market. Biotech is on fire as well.And I’ll tell you all about them in this video. Pacira BioSciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks96th Percentile Overall ScorePCRX MarketRank™: Pacira BioSciences scored higher than 96% of companies evaluated by MarketBeat, and ranked 39th out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingPacira BioSciences has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 4 buy ratings, 4 hold ratings, and 2 sell ratings.Amount of Analyst CoveragePacira BioSciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Pacira BioSciences' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth-11.61% Earnings GrowthEarnings for Pacira BioSciences are expected to decrease by -11.61% in the coming year, from $2.24 to $1.98 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacira BioSciences is 10.17, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.73.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacira BioSciences is 10.17, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 102.90.Price to Book Value per Share RatioPacira BioSciences has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Pacira BioSciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.46% of the outstanding shares of Pacira BioSciences have been sold short.Short Interest Ratio / Days to CoverPacira BioSciences has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Pacira BioSciences has recently decreased by 4.96%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPacira BioSciences does not currently pay a dividend.Dividend GrowthPacira BioSciences does not have a long track record of dividend growth. Sustainability and ESG3.9 / 5Environmental Score-1.89 Percentage of Shares Shorted12.46% of the outstanding shares of Pacira BioSciences have been sold short.Short Interest Ratio / Days to CoverPacira BioSciences has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Pacira BioSciences has recently decreased by 4.96%, indicating that investor sentiment is improving. News and Social Media2.1 / 5News Sentiment0.69 News SentimentPacira BioSciences has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Pacira BioSciences this week, compared to 4 articles on an average week.MarketBeat FollowsOnly 3 people have added Pacira BioSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Pacira BioSciences insiders have bought 29.14% more of their company's stock than they have sold. Specifically, they have bought $136,240.00 in company stock and sold $105,494.00 in company stock.Percentage Held by InsidersOnly 6.40% of the stock of Pacira BioSciences is held by insiders.Percentage Held by Institutions99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pacira BioSciences' insider trading history. Receive PCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address PCRX Stock News HeadlinesExecutive reshuffles: NSC, PCRX and OMI Companies in focusSeptember 28 at 4:21 PM | msn.comPacira BioSciences appoints Lauren Riker as interim CFOSeptember 27 at 9:08 PM | msn.comWho are Nvidia’s New Silent Partners?Nvidia knows it can’t stand still as AI continues to grow at an exponential rate. That’s why CEO Jensen Huang consistently has his company ahead of the curve when it comes to artificial intelligence. Nvidia’s added $2 trillion in market cap in 2024.September 29, 2024 | Weiss Ratings (Ad)Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up on Analyst UpgradeSeptember 27 at 1:32 AM | americanbankingnews.comPacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the KneeSeptember 26 at 8:00 AM | globenewswire.comDOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to ShareholdersSeptember 25, 2024 | prnewswire.comPacira BioSciences (NASDAQ:PCRX) Price Target Raised to $18.00 at Jefferies Financial GroupSeptember 25, 2024 | americanbankingnews.comPacira BioSciences (NASDAQ:PCRX) Shares Up 6.7%September 19, 2024 | americanbankingnews.comSee More Headlines PCRX Stock Analysis - Frequently Asked Questions How have PCRX shares performed this year? Pacira BioSciences' stock was trading at $33.74 on January 1st, 2024. Since then, PCRX stock has decreased by 56.9% and is now trading at $14.54. View the best growth stocks for 2024 here. How were Pacira BioSciences' earnings last quarter? Pacira BioSciences, Inc. (NASDAQ:PCRX) posted its quarterly earnings results on Tuesday, July, 30th. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.53 by $0.11. The business earned $178.02 million during the quarter, compared to the consensus estimate of $173.31 million. Pacira BioSciences had a net margin of 9.21% and a trailing twelve-month return on equity of 13.22%. How do I buy shares of Pacira BioSciences? Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Pacira BioSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV) and Pfizer (PFE). Company Calendar Last Earnings7/30/2024Today9/29/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PCRX CUSIP69512710 CIK1396814 Webwww.pacira.com Phone(813) 553-6680Fax302-655-5049Employees720Year FoundedN/APrice Target and Rating Average Stock Price Target$24.10 High Stock Price Target$57.00 Low Stock Price Target$8.00 Potential Upside/Downside+65.7%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$1.43 Trailing P/E Ratio10.17 Forward P/E Ratio6.49 P/E GrowthN/ANet Income$41.96 million Net Margins9.21% Pretax Margin14.56% Return on Equity13.22% Return on Assets7.24% Debt Debt-to-Equity Ratio0.67 Current Ratio6.82 Quick Ratio5.70 Sales & Book Value Annual Sales$674.98 million Price / Sales0.99 Cash Flow$4.04 per share Price / Cash Flow3.60 Book Value$18.74 per share Price / Book0.78Miscellaneous Outstanding Shares46,130,000Free Float43,567,000Market Cap$670.73 million OptionableOptionable Beta0.84 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:PCRX) was last updated on 9/29/2024 by MarketBeat.com Staff From Our PartnersThe Bible Says it Clear As DayIt came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This pa...Prosperity Research | SponsoredNew September Stock WarningSeptember is the most volatile month of the year for stocks. And after the brutal tech selloff, one Wall St...Chaikin Analytics | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the ...Porter & Company | SponsoredThe $15 "Insider Secret" That Could Save Your RetirementWhat if I told you there's a $15 stock that a billionaire insider just poured $47 MILLION into? That's righ...Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.